Dr. Reddy’s Laboratories Releases Q2 2025 Financial Results

Tip Ranks
2025.10.27 11:17
portai
I'm PortAI, I can summarize articles.

Dr. Reddy’s Laboratories (RDY) announced its Q2 2025 financial results on October 25, 2025, complying with SEBI regulations. The latest analyst rating for RDY is a Buy with a $16.00 price target. Spark’s AI Analyst rates RDY as Outperform, citing strong financial performance and a solid balance sheet. Technical analysis shows mixed signals, with short-term bullish momentum but potential bearish trends. The company, based in Hyderabad, India, focuses on generic medications and has a market cap of $12.2B.

An update from Dr Reddy’s Laboratories ( (RDY) ) is now available.

On October 25, 2025, Dr. Reddy’s Laboratories announced the publication of its unaudited financial results for the quarter and half-year ending September 30, 2025. These results were advertised in the Financial Express and Andhra Prabha newspapers. This disclosure is part of the company’s compliance with the Securities and Exchange Board of India’s regulations, reflecting its commitment to transparency and providing stakeholders with timely financial information.

The most recent analyst rating on (RDY) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.

Spark’s Take on RDY Stock

According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.

Dr Reddy’s Laboratories’ overall stock score reflects strong financial performance and a balanced valuation. The company’s consistent profitability and solid balance sheet are significant strengths. Technical analysis presents mixed signals, with short-term bullish momentum but potential bearish trends. The valuation is fair, with no significant overvaluation concerns. Earnings call insights highlight both growth opportunities and challenges, particularly in the U.S. generics market.

To see Spark’s full report on RDY stock, click here.

More about Dr Reddy’s Laboratories

Dr. Reddy’s Laboratories is a pharmaceutical company based in Hyderabad, India. It is involved in the manufacturing and marketing of a wide range of pharmaceutical products and services, focusing on generic medications and active pharmaceutical ingredients.

Average Trading Volume: 1,050,429

Technical Sentiment Signal: Strong Buy

Current Market Cap: $12.2B

Learn more about RDY stock on TipRanks’ Stock Analysis page.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer